Seminars in Hematology
Volume 46, Issue 4 , Pages 371-377, October 2009

Hereditary Sideroblastic Anemias: Pathophysiology, Diagnosis, and Treatment

  • Clara Camaschella

      Affiliations

    • Corresponding Author InformationAddress correspondence to Professor Clara Camaschella, Università Vita-Salute San Raffaele, Via Olgettina, 60 20132 Milano, Italy

Vita-Salute University and San Raffaele Scientific Institute, Milan, Italy

Inherited sideroblastic anemia comprises several rare anemias due to heterogeneous genetic lesions, all characterized by the presence of ringed sideroblasts in the bone marrow. This morphological aspect reflects abnormal mitochondrial iron utilization by the erythroid precursors. The most common X-linked sideroblastic anemia (XLSA), due to mutations of the first enzyme of the heme synthetic pathway, delta-aminolevulinic acid synthase 2 (ALAS2), has linked heme deficiency to mitochondrial iron accumulation. The identification of other genes, such as adenosine triphosphate (ATP) binding cassette B7 (ABCB7) and glutaredoxin 5 (GLRX5), has strengthened the role of iron sulfur cluster biogenesis in sideroblast formation and revealed a complex interplay between pathways of mitochondrial iron utilization and cytosolic iron sensing by the iron-regulatory proteins (IRPs). As recently occurred with the discovery of the SLC25A38-related sideroblastic anemia, the identification of the genes responsible for as yet uncharacterized forms will provide further insights into mitochondrial iron metabolism of erythroid cells and the pathophysiology of sideroblastic anemia.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by Roche Foundation for Anemia Research (ROFAR).

PII: S0037-1963(09)00104-8

doi:10.1053/j.seminhematol.2009.07.001

Seminars in Hematology
Volume 46, Issue 4 , Pages 371-377, October 2009